UB studies of this rare form of the disease show that grey matter volume, not lesions, are key in severe MS and that novel tools can better assess them.
The Jacobs School is one of the clinical trial sites testing the COVID-19 drug in kids with symptomatic infection who are not hospitalized but are at risk of severe disease.